160 related articles for article (PubMed ID: 37522557)
1. Successes and Challenges in Taming the Beast: Cytotoxic Immune Effectors in Amyotrophic Lateral Sclerosis.
Kaur K; Chen PC; Ko MW; Mei A; Huerta-Yepez S; Maharaj D; Malarkannan S; Jewett A
Crit Rev Immunol; 2023; 43(1):1-11. PubMed ID: 37522557
[TBL] [Abstract][Full Text] [Related]
2. The Potential Role of Cytotoxic Immune Effectors in Induction, Progression and Pathogenesis of Amyotrophic Lateral Sclerosis (ALS).
Kaur K; Chen PC; Ko MW; Mei A; Chovatiya N; Huerta-Yepez S; Ni W; Mackay S; Zhou J; Maharaj D; Malarkannan S; Jewett A
Cells; 2022 Oct; 11(21):. PubMed ID: 36359827
[TBL] [Abstract][Full Text] [Related]
3. Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations.
Bursch F; Kalmbach N; Naujock M; Staege S; Eggenschwiler R; Abo-Rady M; Japtok J; Guo W; Hensel N; Reinhardt P; Boeckers TM; Cantz T; Sterneckert J; Van Den Bosch L; Hermann A; Petri S; Wegner F
Hum Mol Genet; 2019 Sep; 28(17):2835-2850. PubMed ID: 31108504
[TBL] [Abstract][Full Text] [Related]
4. The Potential Role of Cytotoxic Immune Effectors in Amyotrophic Lateral Sclerosis (ALS); A Longitudinal Case Study Comparing Patients with Genetically Identical Healthy Twin.
Kaur K; Chen PC; Ko MW; Huerta-Yepez S; Maharaj D; Jewett A
Crit Rev Immunol; 2023; 43(1):27-39. PubMed ID: 37522559
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development.
Bowerman M; Murray LM; Scamps F; Schneider BL; Kothary R; Raoul C
Eur J Med Genet; 2018 Nov; 61(11):685-698. PubMed ID: 29313812
[TBL] [Abstract][Full Text] [Related]
6. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis.
Pokrishevsky E; Grad LI; Yousefi M; Wang J; Mackenzie IR; Cashman NR
PLoS One; 2012; 7(4):e35050. PubMed ID: 22493728
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic CD8
Coque E; Salsac C; Espinosa-Carrasco G; Varga B; Degauque N; Cadoux M; Crabé R; Virenque A; Soulard C; Fierle JK; Brodovitch A; Libralato M; Végh AG; Venteo S; Scamps F; Boucraut J; Laplaud D; Hernandez J; Gergely C; Vincent T; Raoul C
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2312-2317. PubMed ID: 30674678
[TBL] [Abstract][Full Text] [Related]
8. From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.
Alrafiah AR
In Vivo; 2018; 32(5):983-998. PubMed ID: 30150420
[TBL] [Abstract][Full Text] [Related]
9. IN VITRO AND IN VIVO MODELS OF AMYOTROPHIC LATERAL SCLEROSIS: AN UPDATED OVERVIEW.
Gois AM; Mendonça DMF; Freire MAM; Santos JR
Brain Res Bull; 2020 Jun; 159():32-43. PubMed ID: 32247802
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Cytotoxic Immune Effector Function by AJ3 Probiotic Bacteria in Amyotrophic Lateral Sclerosis (ALS).
Chen PC; Kaur K; Ko MW; Huerta-Yepez S; Jain Y; Jewett A
Crit Rev Immunol; 2023; 43(1):13-26. PubMed ID: 37522558
[TBL] [Abstract][Full Text] [Related]
11. Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient.
Coatti GC; Frangini M; Valadares MC; Gomes JP; Lima NO; Cavaçana N; Assoni AF; Pelatti MV; Birbrair A; de Lima ACP; Singer JM; Rocha FMM; Da Silva GL; Mantovani MS; Macedo-Souza LI; Ferrari MFR; Zatz M
Stem Cell Rev Rep; 2017 Oct; 13(5):686-698. PubMed ID: 28710685
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis.
Nowicka N; Juranek J; Juranek JK; Wojtkiewicz J
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31141951
[TBL] [Abstract][Full Text] [Related]
13. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Jeon GS; Shim YM; Lee DY; Kim JS; Kang M; Ahn SH; Shin JY; Geum D; Hong YH; Sung JJ
Mol Neurobiol; 2019 Mar; 56(3):2007-2021. PubMed ID: 29982983
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis.
Wang T; Tomas D; Perera ND; Cuic B; Luikinga S; Viden A; Barton SK; McLean CA; Samson AL; Southon A; Bush AI; Murphy JM; Turner BJ
Cell Death Differ; 2022 Jun; 29(6):1187-1198. PubMed ID: 34857917
[TBL] [Abstract][Full Text] [Related]
15. The Overexpression of TDP-43 Protein in the Neuron and Oligodendrocyte Cells Causes the Progressive Motor Neuron Degeneration in the SOD1 G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.
Lu Y; Tang C; Zhu L; Li J; Liang H; Zhang J; Xu R
Int J Biol Sci; 2016; 12(9):1140-9. PubMed ID: 27570488
[TBL] [Abstract][Full Text] [Related]
16. Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration.
Trist BG; Fifita JA; Hogan A; Grima N; Smith B; Troakes C; Vance C; Shaw C; Al-Sarraj S; Blair IP; Double KL
Acta Neuropathol Commun; 2022 Aug; 10(1):122. PubMed ID: 36008843
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain.
Gregory JM; Livesey MR; McDade K; Selvaraj BT; Barton SK; Chandran S; Smith C
J Pathol; 2020 Jan; 250(1):67-78. PubMed ID: 31579943
[TBL] [Abstract][Full Text] [Related]
18. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.
Gomez-Deza J; Lee YB; Troakes C; Nolan M; Al-Sarraj S; Gallo JM; Shaw CE
Acta Neuropathol Commun; 2015 Jun; 3():38. PubMed ID: 26108573
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy in Amyotrophic Lateral Sclerosis.
Fang T; Je G; Pacut P; Keyhanian K; Gao J; Ghasemi M
Cells; 2022 Jun; 11(13):. PubMed ID: 35805149
[TBL] [Abstract][Full Text] [Related]
20. [Familial Amyotrophic Lateral Sclerosis].
Suzuki N; Nishiyama A; Kato M; Warita H; Aoki M
Brain Nerve; 2019 Nov; 71(11):1169-1181. PubMed ID: 31722303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
